Electrochemotherapy in the treatment of locally advanced or recurrent eyelid-periocular basal cell carcinomas
Electrochemotherapy in the treatment of locally advanced or recurrent eyelid-periocular basal cell carcinomas
复制标题
DOI：
10.1038/s41598-019-41026-2
复制
发表时间：
2019-03-12
影响因子：
4.6
通讯作者：
Toth-Molnar, Edit
中科院分区：
文献类型：
--
作者：
Kis, Erika Gabriella;Baltas, Eszter;Toth-Molnar, Edit
有越来越多的证据表明电化学疗法（ECT）在治疗头颈部基底细胞癌中的有效性，尽管其在眼睑-眼周皮肤肿瘤治疗中的作用还有待澄清。本研究的目的是评估ECT治疗局部晚期原发性和复发性眼睑-眼周皮肤基底细胞癌的结果。12例基底细胞癌累及眼睑-眼周皮肤区域的患者接受了ECT治疗。3例患者为局部晚期原发性肿瘤，9例患者为复发性肿瘤。根据ESOPE指南，使用Cliniporator TM器械进行所有治疗。所有患者均接受以博来霉素为基础的ECT治疗。3例患者的给药途径为瘤内给药，9例患者为静脉给药。使用RECIST 1.1评价肿瘤缓解。的搜索.所有患者的眼周皮肤肿瘤均获得完全缓解。3例术后出现下睑外翻，需手术矫正。ECT可以有效地用于治疗眼睑-眼周皮肤区域的局部晚期或复发性基底细胞癌。在短时间随访的情况下，可以实现极好的肿瘤控制，具有良好的功能和美容效果，无全身不良事件。
There is increasing evidence about the effectiveness of electrochemotherapy (ECT) in the treatment of basal cell carcinomas in the head and neck region, although its role in the management of eyelid-periocular skin tumors has to be clarified. The aim of the present study is to evaluate the results of ECT in the treatment of locally advanced primary and recurrent eyelid-periocular skin basal cell carcinomas. Twelve patients with basal cell carcinoma involving the eyelid-periocular skin region were treated with ECT. Three patients had locally advanced primary tumors, while 9 patients had recurrent tumors. All treatments were performed according to the ESOPE guidelines, using Cliniporator TM device. All patients received bleomycin based ECT. The route of administration was intratumoral in 3 patients and intravenous in 9 patients. Tumor response was evaluated using the RECIST 1.1. criteria. ECT resulted in complete response of the periocular skin tumors in all patients. Lower eyelid ectropion was developed in 3 patients which had to be corrected surgically. ECT can be used effectively in the treatment of locally advanced or recurrent basal cell carcinomas in the eyelid-periocular skin region. Excellent tumor control can be achieved with good functional and cosmetic results without systemic adverse events with short interval follow-up.